These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 27260521

  • 1. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
    Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
    Sharma P, Watts A, Singh H.
    Clin Nucl Med; 2022 Nov 01; 47(11):948-953. PubMed ID: 35961365
    [Abstract] [Full Text] [Related]

  • 3. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH, Ziegler S, Graner FP, Köhner M, Schachoff S, Blechert B, Wester HJ, Scheidhauer K, Schwaiger M, Maurer T, Eiber M.
    Eur J Nucl Med Mol Imaging; 2016 Oct 01; 43(11):1962-70. PubMed ID: 27207281
    [Abstract] [Full Text] [Related]

  • 4. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.
    J Nucl Med; 2015 Nov 01; 56(11):1697-705. PubMed ID: 26294298
    [Abstract] [Full Text] [Related]

  • 5. [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.
    Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, Sims J, Polson H, Alexoff D, Eckelman WC, Kung HF, Fletcher JW.
    Mol Imaging Biol; 2020 Jun 01; 22(3):752-763. PubMed ID: 31429050
    [Abstract] [Full Text] [Related]

  • 6. Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.
    Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M.
    Mol Imaging Biol; 2019 Jun 01; 21(3):558-566. PubMed ID: 30105521
    [Abstract] [Full Text] [Related]

  • 7. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
    Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M.
    J Nucl Med; 2015 Jun 01; 56(6):855-61. PubMed ID: 25883128
    [Abstract] [Full Text] [Related]

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jun 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 9. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 May 01; 44(5):765-775. PubMed ID: 27900519
    [Abstract] [Full Text] [Related]

  • 10. Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer.
    Green MA, Eitel JA, Fletcher JW, Mathias CJ, Tann MA, Gardner T, Koch MO, Territo W, Polson H, Hutchins GD.
    Nucl Med Biol; 2017 Mar 01; 46():32-35. PubMed ID: 28012435
    [Abstract] [Full Text] [Related]

  • 11. Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.
    Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.
    Theranostics; 2017 Mar 01; 7(18):4359-4369. PubMed ID: 29158832
    [Abstract] [Full Text] [Related]

  • 12. [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.
    Rosar F, Schaefer-Schuler A, Bartholomä M, Maus S, Petto S, Burgard C, Privé BM, Franssen GM, Derks YHW, Nagarajah J, Khreish F, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2022 Nov 01; 49(13):4736-4747. PubMed ID: 35930033
    [Abstract] [Full Text] [Related]

  • 13. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
    Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.
    J Nucl Med; 2018 Apr 01; 59(4):625-631. PubMed ID: 28986512
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.
    Doot RK, Young AJ, Daube-Witherspoon ME, Alexoff D, Labban KJ, Lee H, Wu Z, Zha Z, Choi SR, Ploessl KH, Schubert EK, Lee H, Zhu L, Reddin JS, Karp JS, Kung H, Pryma DA.
    Nucl Med Biol; 2020 Apr 01; 86-87():1-8. PubMed ID: 32361089
    [Abstract] [Full Text] [Related]

  • 15. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2015 Feb 01; 42(2):197-209. PubMed ID: 25411132
    [Abstract] [Full Text] [Related]

  • 16. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun 01; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 17. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
    Lütje S, Gomez B, Cohnen J, Umutlu L, Gotthardt M, Poeppel TD, Bockisch A, Rosenbaum-Krumme S.
    Clin Nucl Med; 2017 Jan 01; 42(1):20-25. PubMed ID: 27846003
    [Abstract] [Full Text] [Related]

  • 18. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B.
    Mol Imaging Biol; 2015 Aug 01; 17(4):575-84. PubMed ID: 26013479
    [Abstract] [Full Text] [Related]

  • 19. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Sep 01; 44(10):1647-1655. PubMed ID: 28589253
    [Abstract] [Full Text] [Related]

  • 20. Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
    Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, Fillare MA, Alexoff D, Karp JS, Kung HF, Pryma DA.
    Mol Imaging Biol; 2022 Oct 01; 24(5):710-720. PubMed ID: 35349040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.